US 9637738
Methods and agents to increase therapeutic dystrophin expression in muscle
granted A61KA61K31/573A61K31/7088
Quick answer
US patent 9637738 (Methods and agents to increase therapeutic dystrophin expression in muscle) held by ReveraGen BioPharma, Inc. expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ReveraGen BioPharma, Inc.
- Grant date
- Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/573, A61K31/7088, A61K45/06, A61P